An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms ELOQUENT-3
- Sponsors Bristol-Myers Squibb
- 27 Sep 2017 Planned End Date changed from 22 Mar 2019 to 22 Apr 2019.
- 27 Sep 2017 Planned primary completion date changed from 19 Sep 2017 to 14 Nov 2017.
- 11 May 2017 Status changed from recruiting to active, no longer recruiting.